Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings to benefit from federal government changes

The significant regulatory change will authorise controlled importation of medical cannabis.
AusCann Group Holdings to benefit from federal government changes
The regulatory change has seen the stock jump up 45% to $0.29

AusCann Group Holdings (ASX:AC8) welcomes the federal government’s move to facilitate faster access to medical cannabis for patients.

The significant regulatory change will authorise controlled importation of medical cannabis by approved suppliers from international sources.

This will allow AusCann to import product ahead of time to meet demand from authorised prescribers and be in a position to more quickly provide patient access.

This will significantly accelerate AusCann’s timeline in being able to supply Australian patients.

Elaine Darby, managing director, commented: “We welcome the decision by the government to accelerate patient access to medicinal cannabis products.

“It is encouraging that they have been listening to patients and doctors and acting on their concerns.”


Background

Medical cannabis company, AusCann, commenced trading on the ASX earlier this month after completing a successful reverse takeover of TW Holdings.

The company raised the maximum $5 million under its prospectus offering by issuing 25 million shares priced at $0.20.

AusCann intends to establish a growing facility in Australia to eventually supply Australian patients with Australian grown and manufactured medicines.

However, until domestic approvals are received, AusCann’s medicinal products will be imported from its partner Canopy Growth Corporation that is globally recognised as one of the leaders in medicinal cannabis.

AusCann is also on track to harvest its first medicinal cannabis crop in Chile in April 2017 through its 50:50 partnership with Fundacion Daya.


Analysis

This regulatory change will drive AusCann’s strategy to deliver high quality, cost effective medicinal cannabis treatments to Australian patients.

As more doctors seek to become authorised prescribers of the medication, AusCann is well placed among the medical community to be the supplier of choice for doctors and patients.

Moreover, this move by the government clearly signals its commitment to bring this medication to patients, Australia-wide.

The regulatory change has seen the stock jump up 45% to $0.29.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

researcher using microscope
September 29 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use